NewGenIvf Group (NASDAQ:NIVF) Director Kong Yiu Cheung Acquires 222,223 Shares of Stock

NewGenIvf Group Limited (NASDAQ:NIVF) Director Kong Yiu Cheung purchased 222,223 shares of NewGenIvf Group stock in a transaction dated Thursday, May 28th. The stock was acquired at an average price of $1.50 per share, for a total transaction of $333,334.50. Following the completion of the acquisition, the director owned 222,223 shares of the company’s stock, valued at approximately $333,334.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Kong Yiu Cheung also recently made the following trade(s):

• On Monday, July 27th, Kong Yiu Cheung purchased 2,500,000 shares of NewGenIvf Group stock. The shares were purchased at an average price of $1.00 per share, for a total transaction of $2,500,000.00.
• On Thursday, June 18th, Kong Yiu Cheung purchased 500,000 shares of NewGenIvf Group stock. The shares were bought at an average price of $1.33 per share, with a total value of $665,000.00.

NewGenIvf Group Price Performance

Shares of NIVF opened at $1.21 on Thursday. NewGenIvf Group Limited has a 1-year low of $1.15 and a 1-year high of $1,539.00. The firm has a 50-day simple moving average of $2.87 and a two-hundred day simple moving average of $11.16. The company has a current ratio of 3.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.16.

Wall Street Analyst Weigh In

NIVF has been the topic of a number of analyst reports. Wall Street Zen raised NewGenIvf Group to a “hold” rating in a research note on Saturday, July 4th. Weiss Ratings reiterated a “sell (d)” rating on shares of NewGenIvf Group in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.